Chronic Disease Management Ups Smoking Abstinence

And, nicotine therapy during practice quit attempt linked to increased incidence of quit attempts

MONDAY, Nov. 28 (HealthDay News) -- A chronic disease management approach is associated with increased short- and long-term abstinence from smoking; and nicotine replacement therapy (NT) during a practice quit attempt (PQA) correlates with increased incidence of any quit attempt, according to two studies published in the Nov. 28 issue of the Archives of Internal Medicine.

Anne M. Joseph, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues compared a telephone-based chronic disease management approach (one-year, longitudinal care [LC]) with an evidence-based treatment approach (eight weeks, usual care [UC]) for treatment of tobacco dependence. At 18 months, 30.2 and 23.5 percent of LC and UC participants, respectively, reported six months of abstinence (unadjusted P = 0.13). Prolonged abstinence at 18 months was predicted by LC treatment; quit attempts in the previous year; baseline cigarettes/day; and smoking within 14 to 21 days of quitting, on multivariable analysis. For those who did not quit, LC resulted in significantly reduced smoking at 12 months versus UC.

Matthew J. Carpenter, Ph.D., from the Medical University of South Carolina in Charleston, and colleagues investigated whether NT within the context of a PAQ results in higher incidence of subsequent attempts to permanently quit smoking than a PQA alone, in 849 individuals currently unmotivated to quit. PQA plus NT was associated with significantly elevated incidence of quit attempts and 24-hour quit attempts than PQA intervention alone. NT had marginally higher floating abstinence, but six-month point prevalence abstinence rates were not different between the groups.

"Nicotine therapy sampling during a PQA represents a novel strategy to motivate smokers to make a quit attempt," Carpenter and colleagues write.

One author of the Joseph study disclosed financial ties to Nabi Biopharmaceuticals. One author of the Carpenter study disclosed financial ties to profit organizations that develop, sell, or promote smoking cessation products. GlaxoSmithKline provided discounted nicotine lozenges for the Carpenter study.

Abstract - Joseph
Full Text (subscription or payment may be required)
Abstract - Carpenter
Full Text (subscription or payment may be required)

Physician's Briefing